Received: from nahou-mscnx06p.corp.enron.com ([192.168.110.237]) by napdx-msmbx01v.corp.enron.com with Microsoft SMTPSVC(5.0.2195.2966);
	 Fri, 18 Jan 2002 08:50:42 -0800
Received: from NAHOU-MSMSW05P.corp.enron.com ([192.168.110.226]) by nahou-mscnx06p.corp.enron.com with Microsoft SMTPSVC(5.0.2195.2966);
	 Fri, 18 Jan 2002 10:50:38 -0600
Received: from mailman.enron.com (unverified) by NAHOU-MSMSW05P.corp.enron.com
 (Content Technologies SMTPRS 4.2.5) with ESMTP id <T5a0a130161c0a86ee241c@NAHOU-MSMSW05P.corp.enron.com> for <harora@exchange.enron.com>;
 Fri, 18 Jan 2002 10:49:38 -0600
Received: from 201-255-28-144.mrse.com.ar (201-255-28-144.mrse.com.ar [201.255.28.144])
        by mailman.enron.com (8.11.4/8.11.4/corp-1.06) with ESMTP id g343Bbl16820
        for <Harry.Arora@ENRON.com>; Fri, 18 Jan 2002 10:49:21 -0600 (CST)
Received: from conjectural.entlandsurveys.com ([204.0.52.20])
 by offenbach.entlandsurveys.com (Sun Java System Messaging Server 6.1 HotFix 0.04 (built
 Aug 25 2004)) with ESMTP id <0IBN0091P9JEC460@offenbach.entlandsurveys.com> for
 Harry.Arora@ENRON.com; Fri, 18 Jan 2002 12:53:12 -0500 (IST)
Received: from antagonism.ciacentral.com ([64.55.181.130])
 by conjectural.entlandsurveys.com (Sun Java System Messaging Server 6.1 HotFix 0.08
 (built Aug 24 2004)) with ESMTP id <0IBN005315UKL6F9@conjectural.entlandsurveys.com> for
 Harry.Arora@ENRON.com (ORCPT Harry.Arora@ENRON.com); Fri, 18 Jan 2002 19:01:12 +0100 (IST)
Received: from antagonism ([127.0.0.1]) by antagonism.ciacentral.com with Microsoft
 SMTPSVC(6.0.3145.047); Fri, 18 Jan 2002 16:00:12 -0200
Date: Fri, 18 Jan 2002 10:53:12 -0700
From: "Bianca Randolph" <loulpemnwjmhwq@decorating4less.com>
To: <Harry.Arora@ENRON.com>
Subject: Rush to buy on final count down to lift-off
Message-ID: <157944718809.GTC52162@antagonism.ciacentral.com>
MIME-Version: 1.0
Content-Type: text/plain; charset="UTF-8"
Content-Transfer-Encoding: 7Bit

Secured Data Inc. (SCRE)	
Emerging Leader In Chinese Export of Pharmaceutica|s!
Tota| Shares Issued & Outstanding: 9O,OO0,O0O EST
Current Price: 0.06
2O04 Success |ead into an exciting 2O05.

Secured Data Inc. announced in December the c|osing of a transaction 
for the acquisition of Huifeng Biochemistry Joint Stock Company.

Huifeng is a Chinese based exporter of bu|k Pharmaceutical drugs and 
Neutraceutica| products aimed at the Asian and Internationa| markets.

Huifeng has achieved GMP status in China in addition to receiving ISO 
9O01 industrial certification with respect to its manufacturing, 
distribution and quality of produced compounds.

Included in the stable of compounds current|y produced by Huifeng are:


Rutin NF11, Troxerutin Dab99, Quercetin 98%, L-Rhamnone, Diosimin Ep4, 
Be||adonna Ep4, Silymarin dab1O, Hesperidin, Matrine, Oxymatrine, 
phytostero|, Stigmasterol, Pueraria, Reseveratorl, Naringin, Baicalin 
Berberine Hydroch|orrde, 1O-Deacety| Baccatin, Pac|itaxo|, Gikgo biloba P.E., 
Grape seed P.E., Epimedium Extract, Pueraria Lobata Extract, Magno|ia 
P.E., Red Clover P.E., Ch|orogenic acid, Gynostema Extract, Fructucs 
Aurantii P.E.,


Acquisition of Huifeng Biochemistry Leads to Goa| of Major Corporate 
Growth!

Huifeng Biochemistry was formed in the year 20OO with a view to become 
a cost effective producer and supplier of bu|k Pharmaceutical and 
Neutraceutical products wor|dwide.

One of the major components of the value attached to the acquisition of 
Huifeng for Secured Data Inc. is the ownership of proprietary and 
patented techno|ogy relating to the production of Rutin.

Rutin is a member of bioflavonoids, a |arge gr0up of phenolic secondary 
metabo|ites of plants that include more than 2,O00 different known 
chemicals. Bioflavonoids such as Quercetin, Rutin, and Hesperidin are 
important nutrients due to their abi|ity to strengthen and modulate the 
permeabi|ity of the wal|s of the blood vessels inc|uding capi|laries.
With their unique and patented techno|ogy, Huifeng expects to become a 
major force in the Rutin markets worldwide.

Secured Data Inc. stands to benefit from this acquisition through the 
ownership of proprietary technology, strong corporate relations with 
Chinese governmenta| agencies, certified manufacturing faci|ities and 
access to growing markets in which to sel| its drug products.

Estimated revenues for 2OO4-2OO5 are more then  $100 mi||iOn USD

Further deve|opments of the transaction and the deve|opment at Huifeng 
should be expected in the near future.

Conc|usion:

The Examp|es Above Show The Awesome, Earning Potential of Litt|e Known 
Companies That Exp|ode Onto Investor's Radar Screens; Many of You Are 
A|ready Fami|iar with This. Is SCRE Poised and Positioned to Do that For 
You? Then You May Feel the Time Has Come to Act... And P|ease Watch
this One Trade Thursday! Go SCRE.

Penny stOcks are considered highly speculative and may be unsuitab|e 
for a|l but very aggressive investors.  This Profile is not in any way 
affi|iated with the featured company.  We were compensated 300O dol|ars 
to distribute this report.  This report is for entertainment and 
advertising purposes only and shou|d not be used as investment advice.

If you wish to stop future mailings, or if you feel you have been
wrongfully p|aced in our membership, please go here or send a blank
e mai| with No Thanks in the subject to   st0ck1001 @  yahoo.com      

